Online Session Search
Scientific Sessions are the core of AACC’s Annual Scientific Meeting with more than 70 symposia taking place Monday – Thursday as 1.5- and 2.5-hour sessions. Scientific Sessions present the latest scientific information on all aspects of laboratory medicine and include a variety of education formats, presentation styles, and audience engagements. Here is a preview of some of the timely topics that will be presented at the 2022 AACC Annual Scientific Meeting. They address some of the lab medicine field's exciting advancements and unique challenges in today's everchanging environment. Visit the full conference program to learn more.
Note: All times below are in U.S. Central Time.
Monday, July 25, 2022 | 10:30 a.m. – 12 p.m. Mobile health is revolutionizing healthcare, providing patients with access to critical services, personal data tracking and doctors, regardless of their location. As the number of health applications for smartphones, wearables, tablets, and other digital technologies grows, more people will use them to take control of their own health. This session will explore mobile health technologies and how digital health is transforming the future of laboratory medicine. Attendees will learn the potential of health data and the challenges of data interconnectivity. Concerns for privacy, security and confidentiality will be discussed through presentation, panel discussion and audience questions. The power of social media for healthcare and the validity of posted information will also be debated.
Monday, July 25, 2022 | 10:30 a.m. – 12 p.m. Changes in the regulation of laboratory-developed tests (LDTs) in the United States (US) has been the subject of debate, proposals, guidance, legislation, and discussion for decades. Multiple legislative bills have been recently introduced into the US congress and viable routes for passage currently exist. These legislative bills propose changes in the regulatory landscape of LDTs that will impact patients, laboratories, and physicians, and have the potential to dramatically alter the practice of medicine in the US. Join experts from leading professional organizations as they discuss key elements of the current legislative proposals, the state of the bills, and address questions posed by the audience. The panel members recently participated in a joint AACC/ACMG/AMP/APC webinar discussing this topic and a robust number of questions across the breadth of legislation and impacts on LDTs. The panel looks forward to an interactive discussion addressing key elements of the legislation and audience questions.
Monday, July 25, 2022 | 2:30 – 4 p.m. Laboratorians are key to equitable healthcare delivery. The session will highlight inequitable clinical chemistry, hematology, and toxicology clinical testing practices and demonstrate the leadership role that clinical laboratorians can take to implement change. The speakers include a clinical chemist and physician-scientist who will deliver case-based scenarios that demonstrate the inequitable ordering practices, analytes used in race-based algorithms, and result interpretations. The participants will be assigned to small groups to discuss the cases and develop customized workflow operations they can implement at their institutions.
Monday, July 25, 2022 | 12:30 – 2 p.m. Preanalytical errors are the leading source of errors in laboratory medicine, accounting up to 70% of total errors seen by the clinical laboratory. Sources of preanalytical error include test ordering, patient preparation, sample collection, sample transportation and sample preparation for testing. In this session, three speakers working at different medical centers will review primary sources of pre-analytical error affecting pediatric and adult patients. The talks are designed to be 25 minutes each using a mix of case-based and expert lecture formats and leaving 15 minutes at the end for a panel discussion. Specific recommendations for how to mitigate these errors will be provided so that attendees can implement some of these changes in their practice.
Tuesday, July 26, 2022 | 10:30 a.m. – 12 p.m. Cardiac troponin is integral to diagnosis of acute myocardial infarction (AMI). Sex-specific differences in high-sensitivity cardiac troponin (hs-cTn) upper reference intervals (URLs/99th-percentiles) have been apparent since their advent, but the clinical significance remains controversial. There is notable debate on how divergence between male and female 99th-percentiles relates to disparities in diagnosis and treatment of AMI/CVD. A pre-requisite to understanding issues related to sex-specific URLs involves dissecting the gender bias widely propagated/promulgated in the medical field. Masculine and feminine people are not regarded equally, beginning from medical training, which engrains that women present “atypically” with chest pain. This session will highlight variations in hs-cTn sex-specific thresholds within clinical guidelines and delineate the biologic and social factors that contribute to differences in cardiac pathophysiology, diagnosis, and treatment of CVD between sexes/genders. Data from cisgender and transgender cohorts will be utilized to illustrate how sex, gender, and bias intersect with cardiovascular medicine.
Tuesday, July 26, 2022 | 10:30 a.m. – 12 p.m. In the past 15 years, the tenure period of the current editorial team of Clinical Chemistry, there has been a considerable research interest in circulating nucleic acids and nucleic acids amplification technology. The advancements led to improved diagnosis and management of a variety of diseases and have been the subject of numerous highly cited articles published in the journal. Reflections on these advances will be discussed in this session by two internationally renowned scientists and leaders in these fields.
Tuesday, July 26, 2022 | 10:30 a.m. – 12 p.m. Given the essential role of the laboratory workforce in the healthcare system, it is especially important both to understand the factors contributing to the challenges that affect the current supply of and pathways into clinical laboratory professions, as well as to determine how to address them. Results from interviews and focus groups conducted for the study, Garcia et al, strongly emphasize that meeting future workforce needs will require actions by and collaboration among a wide range of stakeholders. These groups include the laboratory (e.g., institutions and employers), laboratory training programs, and professional organizations. By implementing the actions outlined in the blueprint developed by the American Society for Clinical Pathology and the University of Washington Center for Health Workforce Studies, they can collectively improve the recognition of the current clinical laboratory workforce, increase the opportunities for new entrants into the workforce, and strengthen the pathways into and among these careers.
Tuesday, July 26, 2022 | 2:30 – 4 p.m. Point-of-care testing (POCT) is laboratory testing conducted close to the site of patient care. Traditionally performed in the hospital setting, the portability and ease-of-use creates the opportunity for POCT to meet clinical needs in new ways. This session will explore how POCT is being deployed in a variety of patient care settings through lecture and interactive discussion with the audience. The clinical utility of POCT and changing needs during the pandemic will be a focus of this session.
Wednesday, July 27, 2022 | 10:30 a.m. – 12 p.m. Medicine is a rapidly evolving discipline requiring constant adaptation, collaboration, and leadership and where a diverse and well-coordinated workforce is essential. This session will explore the impact of a lack of diverse representation and inclusion in laboratory medicine on both practicing laboratorians and our patients, with a focus on healthcare delivery, research funding and initiatives, leadership, and professional development. The session is intended for all members of the laboratory medicine community, regardless of demographic. Through a series of lightening presentations, prerecorded videos from leaders in pathology and laboratory medicine, and a moderated panel discussion, participants will hear stories and examples of successful initiatives promoting diversity, equity, and inclusion gaining valuable insight that they can apply at their respective institutions. Participants will leave this session with a greater understanding of how diversity and inclusion strengthen the fields of laboratory medicine and pathology and with actionable tools for promoting inclusivity.
Wednesday, July 27, 2022 | 10:30 a.m. – 12 p.m. Current barriers to pharmacogenomics implementation include reimbursement, turnaround time, complex reporting and interpretation issues. We describe two preemptive, customized genomic implementation models that utilize validated assays in CLIA laboratories combined with medical records-embedded decision support to enable clinical delivery of pharmacogenomic information within high-value clinical settings. These models facilitate the increasing impact of wider adoption of personalized medicine.
Wednesday, July 27, 2022 | 10:30 a.m. – 12 p.m. This session will focus on how different laboratories use business intelligence dashboards for a variety of common operational decision making and quality assurance monitoring activities. In a series of brief showcase presentations, the speakers will describe the practical considerations for designing and implementing their dashboard and demonstrate its key features. The presentations will cover applications in multiple areas of laboratory medicine using different business intelligence software approaches for comparison. The speakers will describe use of Microsoft PowerBI, Tableau, and Epic Slicer Dicer. They will demonstrate dashboards implemented for blood bank, lab test stewardship, infectious pathogens, and chest pain accreditation.
Wednesday, July 27, 2022 | 2:30 – 5 p.m. This session is intended to present attendees with information on drug testing in meconium and umbilical cord tissue, using technical, practical, and case-related issues to illustrate the benefits and limitations of these matrices. A pediatrician will set the stage by discussing the role of drug testing in Neonatal Abstinence Syndrome and provide classical and non-classical case examples to illustrate clinical workflow. Two experts will then go ‘head to head’ to debate the advantages and disadvantages with meconium- and umbilical cord-based drug testing and how each can serve to identify in utero drug exposure. Join us in this “election” session – complete with entry and exit polling of attendees, a “town hall” for the audience to participate in the debate between the testing experts, and case-based examples of how meconium, cord, or both tests contributed to casework.
Be the first to get all the latest news.